Open AccessCase of ketoacidosis by a sodium‐glucose cotransporter 2 inhibitor in a diabetic patient with a low‐carbohydrate diet
Author(s) -
Hayami Tomohide,
Kato Yoshiro,
Kamiya Hideki,
Kondo Masaki,
Naito Ena,
Sugiura Yukako,
Kojima Chika,
Sato Sami,
Yamada Yuichiro,
Kasagi Rina,
Ando Toshihito,
Noda Saeko,
Nakai Hiromi,
Takada Eriko,
Asano Emi,
Motegi Mikio,
Watarai Atsuko,
Kato Koichi,
Nakamura Jiro
Publication year - 2015
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12330
Subject(s) - diabetic ketoacidosis , medicine , ketoacidosis , diabetes mellitus , endocrinology , carbohydrate , low carbohydrate , weight loss , type 1 diabetes , obesity
We present a case of a 32‐year‐old diabetic woman with Prader–Willi syndrome who developed severe ketoacidosis caused by a sodium‐glucose cotransporter 2 ( SGLT 2) inhibitor, a novel class of antihyperglycemic agents, during a strict low‐carbohydrate diet. At admission, a serum glucose level of 191 mg/ dL was relatively low, though laboratory evaluations showed severe ketoacidosis. This is the first report of ketoacidosis caused by a SGLT 2 inhibitor. It is necessary to not only pay attention when using a SGLT 2 inhibitor in patients following a low‐carbohydrate diet, but also to start a low‐carbohydrate diet in patients treated with a SGLT 2 inhibitor because of a high risk for developing ketoacidosis.